Taevas
United StatesPharmaceuticals
Product Registration
Product Registration for Pharmaceuticals in United States
Taevas Global helps pharmaceutical manufacturers navigate the FDA's rigorous product registration pathways — from NDA and ANDA submissions to BLA filings — so you can achieve market authorization faster and with confidence. Whether you are entering the Un
Market
United States
Industry
Pharmaceuticals
Service
Product Registration
Regulator
FDA Center for Drug Evaluation and Research (CDER)
Timeline
10-12 months standard; 6 months priority review
What We Deliver
Six Pillars of United States Pharmaceuticals Intelligence
Our six interconnected pillars give pharmaceutical manufacturers a complete, end-to-end view of the regulatory, commercial, and operational landscape required to achieve successful FDA product registration in the United States.
01
Regulatory Pathway Analysis
We map the precise FDA registration pathway for your drug product — whether NDA, ANDA, BLA, or 505(b)(2) — based on your molecule, indication, and development stage. Our team benchmarks your product against FDA precedent decisions to identify the fastest and most defensible route. This analysis eliminates costly pathway misalignments before a single dossier page is drafted.
NDA, ANDA, BLA, and 505(b)(2) pathway selection
Precedent-based FDA review timeline benchmarking
Orphan drug, fast track, and breakthrough designation assessment
How It Works
From Brief to Board-Ready Intelligence
Our four-phase engagement takes your pharmaceutical product from initial regulatory assessment through a fully prepared FDA submission package, with clear milestones and transparent communication at every stage.
Step 1 · Day 1-2
Intake and Regulatory Assessment
We begin with a structured intake session to capture your product profile, development history, target indication, and commercialization objectives. Our regulatory leads conduct an immediate high-level assessment to identify the most appropriate FDA registration pathway and flag any known regulatory risks. A project charter and timeline are issued within 48 hours of kickoff.
Taevas Approach
During intake we collect your IND history, clinical study reports, existing CMC data packages, and any prior FDA correspondence. This allows our team to immediately identify pathway-specific data gaps, assess the feasibility of expedited designation requests, and calibrate the project timeline to your commercial launch target. We also assign a dedicated regulatory project manager who serves as your single point of contact throughout the engagement.
Market Snapshot
United States Pharmaceuticals Market at a Glance
$0B
US Pharmaceutical Market Size (2023)
0%
Projected Annual Market Growth (CAGR)
0+
FDA-Regulated Drug Manufacturers
0+
NDA and ANDA Approvals Annually
World's Largest Drug Market
The United States represents the single largest pharmaceutical market globally, accounting for approximately 45 percent of worldwide prescription drug sales. The market is driven by high per-capita drug spending, a largely private payer system, and robust demand for innovative biologics and specialty medicines. For foreign manufacturers, successful FDA registration unlocks access to the most commercially valuable market in the world.
FDA's Rigorous but Predictable Framework
The FDA's Center for Drug Evaluation and Research operates under one of the most transparent and well-documented regulatory frameworks globally, with hundreds of published guidance documents, precedent decisions, and public advisory committee transcripts available to inform submission strategy. While the standard NDA review clock is 12 months and the priority review clock is 6 months, well-prepared submissions with strong pre-submission meeting engagement consistently achieve first-cycle approvals. Companies that invest in early FDA alignment significantly reduce their time to market.
Generic and Biosimilar Growth Driving ANDA Filings
The Hatch-Waxman Act and the Biologics Price Competition and Innovation Act have created highly active ANDA and biosimilar registration pipelines, with FDA receiving over 1,000 ANDA submissions annually. The FDA's Generic Drug User Fee Act program has dramatically reduced ANDA review times, with the agency targeting a 10-month review clock for original ANDAs. This competitive landscape means that speed and quality of submission are critical differentiators for generic manufacturers seeking first-to-file or first-to-market advantages.
Digital and AI Integration in FDA Review
FDA has been actively integrating data analytics and artificial intelligence into its drug review processes, including real-world evidence frameworks and model-informed drug development guidance. Manufacturers that structure their clinical and CMC data in formats compatible with FDA's emerging data standards — including CDISC SEND, SDTM, and ADaM — are experiencing faster review interactions and fewer information requests. Taevas Global helps clients build data submission packages that are optimized for FDA's current and emerging review infrastructure.
What's Included
Everything in Your Report
Every Taevas Global Product Registration engagement for the United States pharmaceutical market delivers a comprehensive, actionable package of regulatory intelligence, submission-ready documents, and strategic guidance tailored to your specific product and commercialization goals.
Regulatory Pathway Assessment Report
A detailed written assessment identifying the optimal FDA registration pathway for your product, including expedited designation opportunities, with a supporting rationale and risk register.
CTD Dossier Package
A fully compiled and quality-reviewed Common Technical Document in eCTD format, covering all required modules and authored to FDA's current content and format expectations.
Pre-Submission Meeting Package
A complete Type B or Type C meeting request package including briefing document, proposed questions, supporting data summaries, and a post-meeting response analysis.
CMC Compliance Gap Report
A module-level CMC gap analysis benchmarked against FDA's current cGMP requirements and applicable product-specific guidance, with a prioritized remediation roadmap.
US Market Access and Payer Landscape Map
A structured overview of the US payer environment for your therapeutic area, including formulary tier benchmarks, prior authorization trends, and reimbursement pathway recommendations.
Labeling Strategy Document
A draft Prescribing Information and Patient Labeling package aligned with FDA's content and format regulations, including a labeling negotiation strategy and key claims justification.
Competitive Intelligence Summary
An analysis of comparable approved products in your therapeutic class, including review timelines, labeling precedents, and post-marketing commitment patterns relevant to your registration strategy.
Post-Approval Maintenance Plan
A structured post-approval program covering annual report obligations, field alert reporting requirements, post-marketing commitment tracking, and a change management protocol for CMC and labeling updates.
Who This Is For
Built for These Situations
First-Time US Entrant
Foreign Pharmaceutical Manufacturer Entering the United States
Your company has an approved product in your home market and is now targeting the United States as the next commercial territory. You have limited in-house FDA regulatory expertise and need a trusted partner to guide you through the NDA, ANDA, or BLA process from strategy through approval. Taevas Global provides the end-to-end regulatory infrastructure you need without the cost of building a full internal US regulatory affairs team.
Outcome
You receive a complete FDA submission package, a clear approval timeline, and a launch-ready market access strategy that positions your product for day-one commercial success in the United States.
Next Steps
After Product Registration, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your United States Opportunity?
Whether you are filing your first NDA, expanding a generic portfolio through ANDA submissions, or preparing a biosimilar BLA, Taevas Global's pharmaceutical regulatory experts are ready to build your FDA registration strategy. Contact us today to begin with a no-obligation consultation.
End-to-end FDA submission support from pathway selection through approval
Dedicated regulatory project manager and subject matter expert team
Pre-submission FDA meeting strategy to maximize first-cycle approval probability
Integrated market access and commercial launch readiness planning